Io Biotech Inc's Customers Performance

Name: Io Biotech Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

IOBT

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


IOBT's Source of Revenues		• List of IOBT Customers

for the same period Io Biotech Inc

• List of IOBT Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Io Biotech Inc's Comment on Sales, Marketing and Customers

News about Io Biotech Inc Contracts

Pre-Clinical Insights from IO Biotech Advancements in Therapeutic Cancer Vaccine Candidates Presented at SITC 2025

At the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), IO Biotech presented compelling pre-clinical data on its additional therapeutic cancer vaccine candidates. This research highlights the company s commitment to advancing immunotherapeutic approaches in oncology. Alongside this, recent market performance indicators suggest a positive outlook for IO Biotech, outperforming broader market trends and demonstrating resilience among its competitive peers.The landscape of cancer treatment is continuously evolving, with immunotherapy leading as a promising frontier. At the recent SITC 2025 Annual Meeting, IO Biotech Inc. emerged as a pivotal player by unveiling new pre-clinical data that un...

Promising Outcomes in Metastatic Lung Cancer IO Biotechs Innovative Vaccine and Keytruda Show Enhanced Efficacy in P...

In a groundbreaking development for the treatment of metastatic non-small cell lung cancer (NSCLC), IO Biotech has reported positive results from its Phase 2 IOB-022 study, evaluating the efficacy and safety of its off-the-shelf therapeutic cancer vaccine, IO102-IO103, in combination with the well-established immunotherapy agent, Keytruda (pembrolizumab). This innovative therapeutic approach aims to harness the immune system in a dual-faceted manner to tackle one of the most challenging cancers known to medical science.The Phase 2 study produced compelling data indicating a considerable overall response rate of 55% (unconfirmed) and 48% (confirmed) among patients receiving the combination treatment in the fi...

IO Biotech's Phase 2 Trial Empowers the Immune System to Combat Solid Tumors

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialIO Biotech, a leading biotechnology company focused on developing novel immune-oncology therapies, has recently announced the successful dosing of the first patient in their Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial. This exciting development marks a major milestone for the company and brings new hope for patients battling various types of solid tumors.Io Biotech s revolutionary approach aims to harness the power of the patient s own immune system to fight cancer. By targeting specific immune pathways, their therapies have shown great potential in improving the patient s response to treatment and over...

IOBT's Stock Performance relative to it's Customers

IOBT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Io Biotech Inc	0.55	0.00	-86.15	19
SUBTOTAL	0.00	0.00	0.00	-

Sources: Io Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Io Biotech Inc’s corporate clients.
For your research, we’ve provided 9 tables on Io Biotech Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.